People who smoke a lot and people without depression might get more benefit
SS: Screening and selection of studies, proofreading/correcting manuscript assisting in drawing conclusions from the extracted data
The longer the gap in treatment, the bigger the jump in risk up to a 22% increase for heart attack, stroke and death after two years off GLP-1s, largely erasing the cardiovascular benefits gained during treatment
Continuous glucose monitoring and the effect of liraglutide in cardiac surgery patients: a substudy of the randomized controlled GLOBE trial
Gastrointestinal AE with cagrisema were more than with semagutide or cagrilintide monotherapy, however the SAE and AE leading to medication discontinuation were minimal and similar between the groups [87, 90] A programme of phase 3 clinical trials (REDEFINE) assessing the safety and efficacy of cagrisema in people with obesity (NCT05567796, NCT05394519, NCT05813925) is currently ongoing